Press release

Please find below Nanobiotix’s latest press releases.
205 result
Nanobiotix Provides Third Quarter Operational and Financial Update
Nanobiotix to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
Nanobiotix announces Red Journal publication of preclinical data showing radioenhancer NBTXR3 may “reprogram” the tumor microenvironment to overcome anti-PD-1 resistance and evoke abscopal effect
Nanobiotix provides business update and reports financial results for the first half of 2021
Nanobiotix To Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Nanobiotix provides second quarter operational and financial update
Nanobiotix Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
Nanobiotix to host virtual KOL event discussing potential first-in-class radioenhancer NBTXR3 in immunotherapy on june 11, 2021
Nanobiotix Reports New Data for Potential First-In-Class Radio­enhancer NBTXR3 in Combination with Anti-Pd-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-Pd-1 Exposure
Nanobiotix Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
Nanobiotix to participate in fireside chat at the Jefferies Virtual Healthcare Conference
Nanobiotix Announces The Appointment Of Dr. Gary Phillips As Chairman Of The Nanobiotix Supervisory Board
Nanobiotix Announces Updated Results From Priority Pathways In Head And Neck Cancer And Immunotherapy For Potential First-In-Class Radioenhancer NBTXR3 At 2021 Annual Meeting Of The American Society For Clinical Oncology
Nanobiotix To Present At The UBS Global Healthcare Virtual Conference
Nanobiotix Partners With Lianbio To Develop And Commercialize Potential First-In-Class Radioenhancer NBTXR3 Across Tumor Types And Therapeutic Combinations In China And Other Asian Markets
Nanobiotix announces first quarter operational and financial updates
Nanobiotix To Present Four Posters Including Updates From Priority Head And Neck Cancer And Immunotherapy Development Pathways At The 2021 Annual Meeting Of The American Society For Clinical Oncology
Nanobiotix Combined Shareholders Meeting To Be Held April 28, 2021: Availability Of Preparatory Documents And Methods For Voting Participation
Nanobiotix Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
Nanobiotix Reports Full Year 2020 Financial Results And Highlights Operational Progress
Nanobiotix and Pharmaengine mutually agree to conclude collaboration
Nanobiotix to present at the H.C. Wainwright Global Life Sciences Conference
Preclinical data presented at AACR virtual special conference showed NBTXR3 combo over­comes anti-PD-1 resistance, pro­motes strong abscopal effect and long-term anti-cancer memory
Nanobiotix announces first patient injected with NBTXR3 in esophageal cancer
Nanobiotix subsidiary Curadigm secures new collaboration agreement with Sanofi focused on gene therapy pipeline
Nanobiotix announces positive first results for novel NBTXR3 in rectal cancer study at ASCO-GI 2021
Nanobiotix announces key development milestones for 2021 after successful Nasdaq initial public offering
Nanobiotix announces closing of underwriters' option to purchase additional ADSs
Nanobiotix announces closing of the global offering and full exer­cise of underwriters' option to purchase additional ADSs, bringing gross proceeds of global offering to $113.3 million
Nanobiotix announces trading resumption of its ordinary shares on Euronext Paris
Nanobiotix announces pricing of global offering and approval to list on nasdaq global select market
Nanobiotix announces temporary trading halt of its ordinary shares on Euronext Paris
Nanobiotix announces the filing of an amended registration statement, including an estimated initial public offering range
Nanobiotix announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
Nanobiotix files registration statement for proposed initial public offering in the United States
Nanobiotix announces two new phase II trials evaluating NBTXR3 in combination with anti-PD-1 for the treatment of head and neck cancer
Nanobiotix announces positive new pre-clinical data suggesting radioenhancer NBTXR3 could have a significant impact in immunotherapy
Nanobiotix announces positive first clinical data showing conversion of anti-PD-1 non-responders to responders with radioenhancer NBTXR3
Nanobiotix provides update on global clinical development plan for first-in-class radioenhancer NBTXR3
Nanobiotix announces four presentations at the Society for Immunotherapy of Cancer (SITC) 35th anniversary annual meeting
Nanobiotix announces first patient injected with NBTXR3 in pancreatic cancer and safe to proceed notifications for two additional trials from U.S. FDA
Nanobiotix announces half-year financial statements as at June 30, 2020
Update to the Nanobiotix press release dated july 28, 2020

Update to the Nanobiotix press release dated july 28, 2020

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Not for access within the United States, Canada, Japan or Australia
Nanobiotix successfully raises approximatively €20 million in placement of ordinary new shares with US and european investors

Nanobiotix successfully raises approximatively €20 million in placement of ordinary new shares with US and european investors

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Not for access within the United States, Canada, Japan or Australia
Nanobiotix launches a placement

Title

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Not for access within the United States, Canada, Japan or Australia
Nanobiotix announces revenue for second quarter 2020 and first half year 2020
Nanobiotix receives feedback from US FDA to advance phase III head and neck cancer study design and CMC development plan for NDA
Nanobiotix spinoff Curadigm validates novel nanoprimer technology in RNA therapeutics
Nanobiotix announces positive first results from phase I expansion in locally advanced head and neck cancer at ASCO 2020
Nanobiotix announces first phase I trial with NBTXR3 in pancreatic cancer is safe to proceed per US FDA
Nanobiotix provides updates on clinical development continuity in the context of the Covid-19 crisis
Scientific Clinical | Nanobiotix announces Fast Track designation granted by U.S. FDA for investigation of first-in-class NBTXR3 in Head and Neck cancer
Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update
Corporate | Nanobiotix receives the 2019 Prix Galien award for first-in-class Hensify
Scientific Clinical | Nanobiotix announces new results from pre-clinical immuno-oncology study at SITC 2019
Financial | Nanobiotix announces third quarter 2019 revenue
Scientific Clinical | Phase I study results show first-in-class NBTXR3 could present as a valuable option for patients with hepatocellular carcinoma or liver metastasis
Financial | Nanobiotix announces half year financial statements of june 30, 2019
Financial | Nanobiotix announces second quarter 2019 revenue
Scientific Clinical | Nanobiotix announces publication of phase III soft tissue sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
Corporate | Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
Corporate | Nanobiotix appoints new chief medical officer as the company evolves after achievement of european market approval
Scientific Clinical | Nanobiotix announces the launch of Curadigm : A new nanotechnology platform for healthcare
Financial | Nanobiotix announces first quarter 2019 revenue
Financial | Laurent Levy, CEO, increases stake in Nanobiotix's capital
Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

The following pages contain information regarding the placement of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares
Scientific Clinical | Nanobiotix announces first ever radioenhancer to receive european market approval
Scientific Clinical | Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
Scientific Clinical | Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
Financial | Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank
Financial | Nanobiotix Plans to Conduct Registered Public Offering in the United States
Scientific Clinical | Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
Financial | Nanobiotix revenues for the 3rd quarter of 2018
Scientific Clinical | NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
Financial | Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank
Scientific Clinical | Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with STS and other ongoing phase I/II trials at ESMO and ASTRO
Scientific Clinical | Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018
Financial | Nanobiotix half year results for the six months ended June 30, 2018
Financial | Nanobiotix signs a 40 M€ non-dilutive financing agreement with the European Investment Bank
Financial | NANOBIOTIX revenue for the 2nd quarter of 2018
Scientific Clinical | Nanobiotix announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
Financial | NANOBIOTIX’ Management statement on recent share price variation
Financial | NANOBIOTIX revenue for the 1st quarter of 2018
Scientific Clinical | Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers
Financial | NANOBIOTIX selected to enter Euronext’s Tech 40 Label
Scientific Clinical | AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
Scientific Clinical | The University of Texas MD Anderson Cancer Center and Nanobiotix have an agreement to run immunotherapeutic pre-clinical research in lung cancer combining NBTXR3 & Nivolumab
Scientific Clinical | Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at American Society Of Clinical Oncology Gastroin­testinal Annual Meeting
Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
Corporate | Nanobiotix: 2017 review and 2018 expected milestones
Scientific Clinical | FDA approves Nanobiotix’s first Immuno-Oncology trial
Financial | Nanobiotix revenues for the 3rd quarter of 2017
Scientific Clinical | Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting
Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3
Financial | Nanobiotix successfully completes approximately eur 27.2 million placement of new shares
Financial | Nanobiotix launches capital increase by means of an accelerated bookbuild offering

Nanobiotix launches capital increase by means of an accelerated bookbuild offering

The following pages contain information regarding the placement of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Scientific Clinical | Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
Scientific Clinical | Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
Financial | Nanobiotix half year results for the six months ended 30 June 2017
Financial | Nanobiotix revenues for the 2nd quarter of 2017
Scientific Clinical | NANOBIOTIX: new translational data presented at ASTRO, NCI AND SITC’S Immunotherapy Workshop
Scientific Clinical | NANOBIOTIX: promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology’s Annual Meeting
Scientific Clinical | NANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-Oncology
Financial | Nanobiotix revenue for the 1st quarter of 2017
Financial | Nanobiotix successfully completes approx. EUR 25.1 million private placement of new shares
Corporate | Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO
Scientific Clinical | NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma
Scientific Clinical | Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017
Corporate | Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer
Corporate | Nanobiotix: 2016 review and 2017 anticipated milestones
Scientific Clinical | Nanobiotix reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial
Scientific Clinical | Nanobiotix Provides Update on Global Development of Lead Product NBTXR3
Scientific Clinical | Nanobiotix presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer
Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
Corporate | Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations
Financial | Bpifrance grants Nanobiotix a 2M€ interest-free loan to support final development stage of lead product, NBTXR3
Corporate | Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe
Financial | Nanobiotix half year results for the six months ended 30 June 2016
Scientific Clinical | Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer
Financial | Nanobiotix announces exercise of warrants by Capital Venture International
Corporate | Nanobiotix receives US$1m milestone payment from PharmaEngine
Scientific Clinical | Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology
Financial | Nanobiotix completes a EUR 21 million private placement
Scientific Clinical | FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer
Scientific Clinical | Nanobiotix’s Soft Tissue Sarcoma pivotal trial progressing well as planned: already 7 countries and 29 sites opened
Financial | Nanobiotix Half Year Results for the period ended 30 June 2015
Scientific Clinical | Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3
Scientific Clinical | Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3
Scientific Clinical | Nanobiotix expands Soft Tissue Sarcoma pivotal clinical trial across Europe and beyond, according to plan
Corporate | Nanobiotix appoints its Manufacturing Partner, CordenPharma : another step towards commercialization
Corporate | Professor Robert Langer joins Nanobiotix as Scientific Advisor
Financial | Nanobiotix secures financing from a major US investor, to address the US market
Scientific Clinical | Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe
Financial | Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers
Scientific Clinical | PharmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific
Financial | Nanobiotix Half year Results for the period ended 30 june 2014
Scientific Clinical | Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO
Financial | Nanobiotix Revenue Q1 2014 and new composition shareholding
Corporate | Nanobiotix appoints Thierry Otin as Head of Manufacturing and supply
Scientific Clinical | Nanobiotix selected to present data from NBTXR3 clinical trial at ASCO
Scientific Clinical | Nanobiotix sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3
Corporate | Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar
Corporate | Nanomedicine Map reveals the European landscape and potential
Scientific Clinical | Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar
Corporate | Nanobiotix honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
Financial | Nanobiotix Half Year Results for the period ended 30 June 2013
Corporate | Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication
Scientific Clinical | Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the NCI for development
Scientific Clinical | Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3
Scientific Clinical | Nanobiotix’s NBTXR3 Achieves Clinical Milestone Reaching Proof-Of- Concept in Phase I Trial of Soft Tissue Sarcoma
Corporate | Dr. Laurent Levy, CEO of Nanobiotix, receives the UB Entrepreneurship Award from the University at Buffalo, SUNY
Corporate | Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference
Corporate | Nanobiotix appoints Dr Alain Herrera to the Supervisory Board
Corporate | Nanobiotix 2013 Review Significant Corporate and Clinical Progress
Corporate | Laurent Levy, CEO Nanobiotix, elected Vice-Chairman of the ETPN
Scientific Clinical | Phase I Independent Data Monitoring Committee confirms good safety of NBTXR3 in the first group of patients with advanced STS
Corporate | Nanomed2020 intends to bring more nanomedicine products to European patients
Corporate | PharmaEngine and Nanobiotix Sign Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3
Scientific Clinical | Nanobiotix and Thomas Jefferson University Start Research Collaboration
Corporate | Nanobiotix appoints Dr. Bernd Muehlenweg as a member of the Executive Board
Scientific Clinical | Nanobiotix Starts Clinical Trial with Lead Product NBTXR3
Corporate | Nanobiotix announces changes to the non-executive board
Corporate | Nanbiotix welcomes Dr Bernd Mühlenweg as Head of Business Development
Corporate | Nanobiotix welcomes Laurent Condomine on board
English